Fusion and Cyteir refocus pipelines; Nona Biosciences collaborating with PharmaEssentia
Several biotechs are looking to make changes to their pipelines as the quarter has drawn to a close.
Massachusetts-based Cyteir said Wednesday it is going to focus on CYT-0851, which is designed to be used in combination with capecitabine as a treatment for advanced ovarian cancer. For its preclinical DNA polymerase theta inhibitor program, it plans to out-license the program, the company announced in its Q1 report.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.